Related Experiment Video
Updated: Mar 30, 2026
08:26
Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
Published on: June 14, 2018
12.6K
Immunogenicity evaluation strategy for a second-generation therapeutic, PEG-IFN-β-1a
Joleen T White1,2, Mary Crossman1, Kelly Richter1
1Biogen, 22 Binney Street, Cambridge, MA 02142, USA.
Bioanalysis
|November 7, 2015
Summary
Monitoring immunogenicity is crucial for pegylated interferon-beta-1a (PEG-IFN-β-1a) in multiple sclerosis. This study adapted existing assays to evaluate PEG-IFN-β-1a immunogenicity, highlighting challenges in assessing new therapeutics.
Area of Science:
- Pharmacology
- Immunology
- Biotechnology
Background:
- Neutralizing antibodies can reduce the effectiveness of interferon-beta (IFN-β) in multiple sclerosis (MS) patients.
- Monitoring immunogenicity is critical for the clinical development of novel therapeutic agents, particularly second-generation products.
Purpose of the Study:
- To assess the immunogenicity of a second-generation pegylated interferon-beta product, PEG-IFN-β-1a.
- To establish assay cut points and relevant titer levels for PEG-IFN-β-1a immunogenicity during clinical development.
Main Methods:
- Utilized previously established assays for IFN-β-1a immunogenicity evaluation.
- Modified assays to incorporate current best bioanalytical practices for PEG-IFN-β-1a.
- Employed a separate testing paradigm to monitor antibodies against polyethylene glycol (PEG).
Main Results:
- Established in-study assay cut points and relevant titer levels for PEG-IFN-β-1a.
- Demonstrated the feasibility of adapting legacy assays for second-generation therapeutics.
- Identified challenges associated with assessing the immunogenicity of modified biologics.
Conclusions:
- Immunogenicity evaluation strategies for next-generation therapeutics require balancing current bioanalytical standards with legacy assay consistency.
- Data comparison and interpretation are facilitated by maintaining consistency with previous assays.
- This study provides insights into the complexities of evaluating the immunogenicity of advanced biologic therapies.
